Pointing a laser at the cancer protein everyone gave up on - and reading its mind, one tiny twitch at a time.
In a lab at 2 Tower Place, an instrument fires light at a sheet of cancer protein and watches what bounces back. Not whether the protein is there - everyone can see that - but whether it just flinched. That flinch is the whole company.
Quanta Therapeutics is a clinical-stage biopharmaceutical company with roughly 36 people, a pipeline of oral pills, and an unfashionable obsession: KRAS, the most common cancer-causing gene in human biology, and for forty years the one drug hunters politely agreed was impossible to touch. Today Quanta's lead molecule is in patients. Its second has FDA clearance. A third is in the wings. None of this was supposed to be possible, which is roughly the point.
"Conformational blockade of RAS in cancer." Four words. A decade of people insisting it couldn't be done.
Here is the uncomfortable arithmetic. KRAS mutations drive about one in four human cancers - pancreatic, colorectal, lung, endometrial. They are everywhere the prognosis is worst. And until very recently, oncologists had exactly zero drugs that hit KRAS directly. The protein is small, smooth, and offers nothing for a drug to grab. The textbooks called it "undruggable," which in medicine is the polite word for "we are stuck."
When the first KRAS drugs finally arrived, they hit a single variant - G12C. A genuine breakthrough, and also a narrow one: G12C accounts for only about 10% of KRAS-driven cancers. The other 90% - the G12D and G12V mutations that dominate pancreatic and colorectal disease - stayed exactly as untreatable as before. The party started, and most of the patients weren't invited.
Current G12C inhibitors reach roughly one in ten KRAS cancers. Quanta built its whole company for the other nine.
Quanta was formed in 2018 inside Sofinnova Investments, with Perry Nisen, MD, PhD as founding Executive Chairman and, from June 2021, CEO. Nisen is a physician-scientist who has spent a career where the hard oncology problems live - oncology lead and interim Chief Medical Officer at GlaxoSmithKline, then CEO of the Sanford Burnham Prebys research institute. He has watched plenty of "undruggable" targets, which is perhaps why he was willing to take a bet on one.
The bet was this: stop trying to block KRAS head-on, and instead change its shape. Proteins are not statues; they flex between active and inactive conformations. Find a small molecule that locks the harmful shape - allosteric modulation, in the jargon - and you sidestep the smooth, gripless surface entirely. The catch is that you need to see those shape changes, and they are vanishingly subtle. Which is where the physics comes in.
Most drug hunters ask whether a molecule binds. Quanta asks a stranger question: did the protein change its mind?
Physician-scientist. Ex-GSK oncology lead and interim CMO, former CEO of Sanford Burnham Prebys, Sofinnova executive partner. Founded Quanta in 2018.
Chief Operating Officer, steering the company from platform to clinic.
Chief Medical Officer, running the Phase 1 programs in real patients.
Chief Business & Financial Officer, keeping $142M+ of venture capital pointed at the science.
The platform is called Second Harmonic Generation, or SHG. The physics is the same effect that turns an invisible infrared beam into the green dot of a laser pointer: shine intense light through certain materials and the light doubles its frequency. Crucially, the strength of that doubled signal depends on the precise orientation of the molecules it passes through. Tether a protein to a surface, hit it with a laser, and the SHG signal becomes a live readout of the protein's shape. When a candidate drug nudges KRAS into a new conformation, the signal shifts. The protein, in effect, tells on itself.
Around that readout Quanta runs high-throughput screening plus old-fashioned medicinal chemistry to turn hits into drug-like oral molecules. The pipeline that has come out of it:
Oral, G12D-preferring multi-KRAS inhibitor. In Phase 1 dose expansion - alone and with cetuximab - for pancreatic, colorectal and endometrial cancers.
Oral, G12V-preferring, dual ON/OFF-state multi-KRAS inhibitor. Cleared to begin Phase 1 - Quanta's third IND in about a year.
Pan-KRAS candidate built to cover a broad sweep of KRAS mutations at once.
Earlier-stage hunt for allosteric handles on the wider RAS signaling complex.
The same physics that makes a laser pointer green is the reason a pancreatic cancer patient may one day swallow a pill.
Quanta forms with Perry Nisen as Executive Chairman, built around the SHG platform and an allosteric thesis on RAS.
The founding chairman steps in to run the company as it moves from discovery toward the clinic.
Oversubscribed round co-led by Surveyor Capital and Vida Ventures to advance RAS-targeting programs.
Led by Avidity Partners. Total raised since inception passes $142M, funding the march into the clinic.
FDA greenlights the G12V-preferring inhibitor - the third Quanta IND in roughly twelve months.
Quanta presents safety, tolerability, PK and preliminary efficacy data for its lead G12D inhibitor in solid tumors.
A platform is a promise. Three FDA INDs in about a year is a track record. Quanta has taken QTX3034 from optical bench to dose-expansion cohorts in patients with KRAS G12D pancreatic, colorectal and endometrial cancers - some of the bleakest diagnoses in oncology - and presented its first human safety and preliminary efficacy data in October 2025. The capital backing that work reads like a who's-who of life-science investors.
The Series D was led by Avidity Partners, with Sofinnova Investments, Vida Ventures, Surveyor Capital (a Citadel company), Longitude Capital, BVF Partners and AbbVie Ventures alongside. AbbVie's venture arm has stuck around since the earlier rounds - the kind of repeat strategic interest that tends to mean someone with a drug-development habit is paying close attention.
"With this additional funding, we will be well positioned to rapidly advance our two lead KRAS programs into the clinic in 2024."
Quanta operates in a crowded room - Amgen, Mirati, Revolution Medicines and Roche are all chasing RAS. Most of them started with G12C. Quanta's edge is the part of the map the others walked past.
Quanta's stated aim is best-in-class allosteric inhibitors for RAS-driven cancers - drugs that widen the range of treatable KRAS tumors while dodging the resistance mechanisms that blunt existing therapies. That last part matters. Cancer is good at learning around a drug; an allosteric approach that locks the protein's shape, rather than competing for its surface, is a bet on staying a step ahead of resistance.
The word "undruggable" has an expiry date. Quanta is one of the companies trying to set it.
If Quanta is right, the win is not abstract. It is a person with stage-four pancreatic cancer - a disease that has barely moved in decades - reaching for an oral pill instead of a brochure of bad options. It is the 90% of KRAS patients who watched the first wave of drugs arrive for someone else. Phase 1 is a long way from approval, and most drugs that enter the clinic never leave it. Quanta knows the odds. It is enrolling the patients anyway.
Return to that lab at 2 Tower Place. The instrument fires its light at a sheet of cancer protein and watches for the flinch. Eight years ago that flinch was a hypothesis. Today it is three INDs, a molecule in patients, and $142 million worth of investors betting the readout is real. The protein everyone called untouchable is, at minimum, now being touched - carefully, with a laser, by a company small enough to fit in one building and stubborn enough to aim at the targets the field skipped.
The undruggable target got a Phase 1 trial. That is the entire story - and Quanta is only on chapter one.